Member
news&Notes
Incyte’s Commitment: Advancing Scientific Innovation in Delaware and Beyond
CONTRIBUTED BY INCYTE
Incyte is a global biopharmaceutical company committed to the relentless pursuit of science that can improve the lives of patients, make a difference in health care, and build sustainable value for our stakeholders. Our unique expertise in medicinal chemistry and biology have enabled us to create diversified clinical candidates, the majority of which were discovered by Incyte scientists. We strive to discover and develop first-inclass and best-in-class medicines, and we are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity. Our drug discovery and development efforts were founded in 2002 in Wilmington, Delaware, by a team of 23 research scientists, chemists, and biologists. We have since been actively
››
6
contributing to the growth of Delaware’s science and health care ecosystem. As our portfolio grows, our team has grown with it. Today, Incyte is home to a talented team of more than 2,000 people, including more than 800 world-class scientists who are leading the field of biopharmaceutical research. We have taken the best talent from both academia and industry to support our growing portfolio, and we currently have operations in North America, Europe, and Asia. Our size and approach enable every Incyte employee to contribute to the success of the company and to deliver on our goal of finding solutions for patients with serious unmet medical needs. In 2020, three new products from the Incyte portfolio were approved by the U.S. Food and Drug Administration (FDA). Additionally, Incyte Dermatology was
established in 2020 as a new Commercial franchise in the U.S. and includes a dedicated team of leading dermatology specialists for the development and commercialization of our dermatology portfolio. We are working to leverage our cross-program knowledge of the JAKSTAT pathway to explore the potential of JAK inhibition in a number of immunemediated dermatologic conditions including atopic dermatitis, vitiligo, and hidradenitis suppurativa. In addition to making a difference in the lives of patients, giving back to our communities is an integral part of the Incyte culture. We are proud to work in partnership with stakeholders across the state of Delaware on initiatives intended to support local innovation, continuing education, economic development, and talent recruitment.
Novem b e r / Dec em b e r 2021 | DELAWARE BUSINESS
